Important drugs have been withdrawn from the market due to their blocking effects on the hERG channel, leading to life threatening arrhythmias in patients (acquired LQTS). This prompted regulatory agencies to require preclinical testing of all pharmaceuticals to exclude unwanted side effects due to hERG channel inhibition. Cytocentrics determines potential blocking effects of drug candidates using the patch clamp technique.

Cytocentrics hERG Safety Screening Service includes:

• Study design according to ICH guideline S7B.  
• GLP or non-GLP compliant.
• Whole cell patch clamp recordings.
• IC 50 determination from hERG tail current.
• Use of validated and quality assured Instant Cells.
• Repetitive measurements for each compound concentration.
• Positive and negative control experiments.
• Full scientific report.